CITYSCAPE is a phase II, randomized, double-blind, placebo-controlled trial, which showed an improved ORR and PFS in the anti-TIGIT with anti-PD-L1 therapy combination with more significant benefit observed in the PD-L1 tumor proportion score (TPS) ≥ 50%. Here, CD274 is linked to neoplasm.